Pharmidex

Activities: Research & Development

Trending Articles

  1. Lonza appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer As of 1 July 2025, Andreas joins Lonza’s Executive Committee as Chief Legal & Corporate Affairs Officer
  2. Famar Group acquires German sterile injectable production site from MiP Pharma The fill-finish facility will enhance Famar's footprint in aseptic and lyophilised therapeutic production, allowing the company to better serve its European clients
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    How to protect your workers with emergency showers In manufacturing environments where chemical exposure is a constant risk, the safety and well-being of your workforce should be a top priority, reports James Hamilton, Global...
  4. SCHOTT Pharma delivers strong second quarter of fiscal year 2025 SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, today published its results for the second quarter of the fiscal year 2025
  5. Next generation module improves flow process automation Vapourtec unveils Reaction Controller and Datalogger module

Upcoming event

CPhI North America

20–22 May 2025 | Exhibition | Pennsylvania, US See all

Related Content

Research & Development

Pharmidex moves onto the Stevenage Bioscience Catalyst campus

Modern facilities encourage dialogue and interaction between companies and researchers on the site
Research & Development

MRCT and Pharmidex form drug discovery collaboration

Pharmidex will provide all in vivo ADME/PK drug discovery support to MRCT in 2010
Research & Development

Domainex and Pharmidex form drug discovery services alliance

Contract research company Domainex, based in Cambridge, UK and Pharmidex have agreed to combine their expertise and innovative technologies to provide the market with an integrated, high-quality drug discovery services platform.
Subscribe now